Grazia Vernaci

8PUBLICATIONS
21CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersClinical midwiferyTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 24, 2024
Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2- Breast Cancer.

Michele Bottosso, Federica Miglietta, Grazia Maria Vernaci

|May 20, 2022
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment.

Federica Miglietta, Gaia Griguolo, Michele Bottosso

|Nov 25, 2021
Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer.

Federica Miglietta, Gaia Griguolo, Michele Bottosso

|Oct 20, 2021
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial.

Maria Vittoria Dieci, Valentina Guarneri, Anna Tosi

|Oct 13, 2021
Evolution of HER2-low expression from primary to recurrent breast cancer.

Federica Miglietta, Gaia Griguolo, Michele Bottosso

Pageof 2